Predict your next investment

Corporation
zaluvida.com

See what CB Insights has to offer

Investments

1

About Zaluvida

Zaluvida is a full circle life science group. Its passion is creating ground breaking health products. By using unique bioactive compounds extracted from nature Zaluvida pioneers in tackling some of the world's big health challenges like obesity, antibiotic resistance and livestock emissions.

Zaluvida Headquarters Location

Avenue des Uttins 1

Rolle, 1180,

Switzerland

+41 21 822 23 50

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Zaluvida News

Experts drive Neem Biotech’s efforts to counter effects of antimicrobial resistance on treatment of lung infections

Nov 9, 2017

November 9, 2017 Neem Biotech, the Welsh-based fundamental Research and Development arm of the Zaluvida group of life science companies, is pleased to present an interview with two thought leaders in the field of bacterially-caused chronic lung infections. Experts, respectively, in the fields of infectious diseases and drug development, Dr. Michael Graz and Dr. Graham Dixon have in excess of 40 years of experience between them in understanding bacteria and developing new interventions for life limiting diseases.Together, Dr. Graz and Dr. Dixon are driving Neem Biotech’s efforts to develop a new and effective intervention aimed at countering the effects of resistance to existing antibiotics currently prescribed as the mainstay of management of chronic Pseudomonas aeruginosa caused lung infections in people with cystic fibrosis (CF). Managing Director of Neem Biotech, Dr. Graz said: Antimicrobial resistance is one of the largest health and economic challenges of our time. It has a particularly profound impact on people with CF as current antibiotics are the mainstay of treatment for the bacterially-caused lung infections that cause the highest number of deaths amongst this group of people. Many of these bacteria have unequivocally demonstrated resistance to these antibiotics.Neem Biotech is committed to using our combined in-house expertise to develop a new antimicrobial treatment that circumvents this resistance. Dr. Dixon, Neem Biotech’s Chief Operating Officer and the person tasked with driving Neem Biotech’s clinical development program, added: We realize that overcoming the challenge of antimicrobial resistance cannot be achieved alone. As the North American Cystic Fibrosis Conference is the world’s premier gathering of stakeholders in the CF community, it made sense for Neem to join our CF community colleagues here to add our voice to current deliberations. Their joint message is: It is only through using our individual strengths to work towards a common goal that we will make meaningful headway in managing both antimicrobial resistance and CF. That goal has to be a life without limits for people living with CF. Details of the interview can be found at https://www.news-medical.net/news/20171103/An-alternative-approach-to-augmenting-the-effect-of-antibiotics-in-chronic-CF-lung-infections.aspx . Neem Biotech is developing an adjunct to existing antibiotics that has demonstrated the ability to enhance the effect of these antibiotics in early stage testing. Source:

Zaluvida Investments

1 Investments

Zaluvida has made 1 investments. Their latest investment was in TargEDys as part of their Series A - III on April 4, 2017.

CBI Logo

Zaluvida Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/11/2017

Series A - III

TargEDys

$3.71M

Yes

2

Date

4/11/2017

Round

Series A - III

Company

TargEDys

Amount

$3.71M

New?

Yes

Co-Investors

Sources

2

Zaluvida Team

3 Team Members

Zaluvida has 3 team members, including current Chief Executive Officer, Christoph Staeuble.

Name

Work History

Title

Status

Thomas Hafner

Founder

Current

Christoph Staeuble

Chief Executive Officer

Current

Rajiv Kakar

Chief Information Officer

Former

Name

Thomas Hafner

Christoph Staeuble

Rajiv Kakar

Work History

Title

Founder

Chief Executive Officer

Chief Information Officer

Status

Current

Current

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.